Oncotarget

Research Papers:

A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT)

Xiaobing Wang, Xiuyi Zhi, Zhaogang Yang, Haimei Tian, Yanfen Li, Mo Li, Wenya Zhao, Chao Zhang, Teng Wang, Jing Liu, Di Shen, Cuining Zheng, Dan Zhao, Sheng Yang, Jun Qi, Hongwu Xin, Alexander Stojadinovic, Itzhak Avital, L. James Lee, Jianyu Rao and Wei Zhang _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2017; 8:45345-45355. https://doi.org/10.18632/oncotarget.17477

Metrics: PDF 748 views  |   HTML 1402 views  |   ?  


Abstract

Xiaobing Wang1,*, Xiuyi Zhi2,*, Zhaogang Yang3,*, Haimei Tian1, Yanfen Li1, Mo Li1, Wenya Zhao1, Chao Zhang1, Teng Wang1, Jing Liu1, Di Shen4, Cuining Zheng4, Dan Zhao5, Sheng Yang6, Jun Qi4, Hongwu Xin7,8, Alexander Stojadinovic9, Itzhak Avital10, L. James Lee3, Jianyu Rao1, Wei Zhang1

1Tumor Marker Research Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

2Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, PR China

3NSF Nanoscale Science and Engineering Center (NSEC), The Ohio State University, Columbus, OH, USA

4Laboratory of Clinical Biochemistry, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

5Department of Gynecological Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

6Department of Medicine, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

7The First Peoples’ Hospital of Jingzhou City, The First Hospital and Clinical Medical School of Yangtze University, Jingzhou, PR China

8Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Huber, PR China

9Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

10P8-Medicine Ltd, Sussex, DE, USA

*These authors contributed equally to this work

Correspondence to:

Wei Zhang, email: zhangww1954@126.com

Keywords: lung cancer, biomarker, early detection, MIC-1, screening

Received: February 03, 2017     Accepted: April 14, 2017     Published: April 27, 2017

ABSTRACT

Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17477